Luxembourg Cancer Institute Launches Precision Oncology Study
November 14, 2018Luxembourg’s Institut National du Cancer (INC) announced today that it has begun an initiative to evaluate the use of molecular diagnostics in cancer treatment.
Called MDLUX2, the three-year program will use a standardized set of molecular diagnostics to analyze tissue samples from hundreds of cancer patients recruited through local hospitals. The resulting data will be used to characterize the mutations driving patients’ tumors and inform treatment decisions.